Tobramycin inhalation - PARI Pharma

Drug Profile

Tobramycin inhalation - PARI Pharma

Alternative Names: PARI Tobramycin 100; T 100 - PARI; Tobramycin Pari; Vantobra

Latest Information Update: 26 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PARI Pharma GmbH
  • Developer Centre for Human Drug Research; PARI Pharma GmbH
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Registered Cystic fibrosis-associated respiratory tract infections
  • Phase II Asthma

Most Recent Events

  • 20 Dec 2017 Phase-II clinical trials in Asthma in Netherlands (Inhalation) (EudraCT2017-003177-34)
  • 15 Mar 2016 Biomarkers information updated
  • 18 Mar 2015 Registered for Cystic fibrosis-associated respiratory tract infections in European Union, Liechtenstein, Iceland and Norway (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top